Alnylam Pharmaceuticals Inc. (ALNY): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALNY POWR Grades
- ALNY scores best on the Quality dimension, with a Quality rank ahead of 68.02% of US stocks.
- ALNY's strongest trending metric is Growth; it's been moving up over the last 179 days.
- ALNY ranks lowest in Stability; there it ranks in the 28th percentile.
ALNY Stock Summary
- ALNYLAM PHARMACEUTICALS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 1.39% of US listed stocks.
- With a price/sales ratio of 29.32, ALNYLAM PHARMACEUTICALS INC has a higher such ratio than 95.2% of stocks in our set.
- ALNY's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 95.18% of US stocks.
- Stocks that are quantitatively similar to ALNY, based on their financial statements, market capitalization, and price volatility, are CYTK, ARGX, INSM, DCTH, and MIRM.
- Visit ALNY's SEC page to see the company's official filings. To visit the company's web site, go to www.alnylam.com.
ALNY Valuation Summary
- ALNY's price/sales ratio is 29.4; this is 1334.15% higher than that of the median Healthcare stock.
- Over the past 227 months, ALNY's price/sales ratio has gone down 406.1.
Below are key valuation metrics over time for ALNY.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ALNY | 2023-01-20 | 29.4 | -417.7 | -23.9 | -28.0 |
| ALNY | 2023-01-19 | 29.3 | -415.7 | -23.8 | -27.9 |
| ALNY | 2023-01-18 | 29.7 | -421.6 | -24.1 | -28.3 |
| ALNY | 2023-01-17 | 29.9 | -425.1 | -24.3 | -28.5 |
| ALNY | 2023-01-13 | 30.2 | -428.4 | -24.5 | -28.7 |
| ALNY | 2023-01-12 | 29.4 | -418.1 | -23.9 | -28.0 |
ALNY Growth Metrics
- The 4 year revenue growth rate now stands at 386.49%.
- The 3 year revenue growth rate now stands at 919.64%.
- Its 4 year cash and equivalents growth rate is now at 173.43%.
The table below shows ALNY's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 960.918 | -559.437 | -1,182.123 |
| 2022-06-30 | 884.245 | -578.189 | -980.717 |
| 2022-03-31 | 879.98 | -577.226 | -892.874 |
| 2021-12-31 | 844.287 | -641.693 | -852.824 |
| 2021-09-30 | 749.314 | -614.696 | -837.904 |
| 2021-06-30 | 687.534 | -590.986 | -886.681 |
ALNY's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ALNY has a Quality Grade of C, ranking ahead of 30.65% of graded US stocks.
- ALNY's asset turnover comes in at 0.22 -- ranking 188th of 681 Pharmaceutical Products stocks.
- QGEN, TXMD, and KMDA are the stocks whose asset turnover ratios are most correlated with ALNY.
The table below shows ALNY's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.220 | 0.833 | -0.249 |
| 2021-06-30 | 0.204 | 0.833 | -0.267 |
| 2021-03-31 | 0.171 | 0.832 | -0.272 |
| 2020-12-31 | 0.159 | 0.842 | -0.308 |
| 2020-09-30 | 0.141 | 0.832 | -0.372 |
| 2020-06-30 | 0.130 | 0.853 | -0.416 |
ALNY Price Target
For more insight on analysts targets of ALNY, see our ALNY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $184.16 | Average Broker Recommendation | 1.64 (Moderate Buy) |
ALNY Stock Price Chart Interactive Chart >
ALNY Price/Volume Stats
| Current price | $231.59 | 52-week high | $242.97 |
| Prev. close | $229.02 | 52-week low | $117.58 |
| Day low | $228.77 | Volume | 551,111 |
| Day high | $234.02 | Avg. volume | 727,571 |
| 50-day MA | $226.64 | Dividend yield | N/A |
| 200-day MA | $186.78 | Market Cap | 28.49B |
Alnylam Pharmaceuticals Inc. (ALNY) Company Bio
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics[3] for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.[4] In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. (Source:Wikipedia)
Latest ALNY News From Around the Web
Below are the latest news stories about ALNYLAM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ALNY as an investment opportunity.
Alnylam Pharmaceuticals In-Line Revenue & A Full Slate Of Clinical Read-Outs (ALNY)Alnylam shares have continued to outperform since my last update, besting the XBI ETF by about 10%. Find out why I''m bullish on ALNY stock. |
Alnylam preliminary FY22 net product revenues for 4 drugs rises 35% Y/YAlnylam Pharmaceuticals (ALNY) said preliminary full year global net product revenues for its drugs Onpattro, Amvuttra, Givlaari and Oxlumo amounted to $894M, growing +35% Y/Y (+43% Y/Y… |
Alnylam Announces Preliminary Q4 Global Net Product RevenuesWASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) announced its preliminary fourth quarter 2022 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO.Preliminary global… |
Alnylam (ALNY) Posts Strong Preliminary Revenues for 4Q & FY22Alnylam (ALNY) reports strong preliminary product revenues for its marketed drugs, Onpattro, Amvuttra, Givlaari and Oxlumo for the fourth quarter and full year of 2022. |
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional UpdatesAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2022 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO and provided additional updates on the products’ commercial launches. Preliminary Fourth Quarter and Full Year 2022 Commercial and Financial Performance* Total TTR: |
ALNY Price Returns
| 1-mo | -0.31% |
| 3-mo | 13.24% |
| 6-mo | 63.05% |
| 1-year | 77.98% |
| 3-year | 97.89% |
| 5-year | 72.33% |
| YTD | -2.55% |
| 2022 | 40.14% |
| 2021 | 30.48% |
| 2020 | 12.85% |
| 2019 | 57.96% |
| 2018 | -42.61% |
Continue Researching ALNY
Want to do more research on Alnylam Pharmaceuticals Inc's stock and its price? Try the links below:Alnylam Pharmaceuticals Inc (ALNY) Stock Price | Nasdaq
Alnylam Pharmaceuticals Inc (ALNY) Stock Quote, History and News - Yahoo Finance
Alnylam Pharmaceuticals Inc (ALNY) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...